As such, the absence of renoprotection in our study should not be viewed as precluding a favourable outcome in kidney disease in individuals with diabetes where a range of non-hemodynamic effects afforded by SGLT2 inhibition may underlie their potential beneficial effects. Here, SLC5A2 is linked to kidney disorder.